← All causality assessments
Causality: well established
Causality assessment · Causality: well established
Cenobamate and Eosinophilia: is the FAERS signal real?
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Cenobamate ↔ Eosinophilia
n=32 co-reports · PRR 4.6 · ROR 4.6
Cenobamate is a newer antiepileptic; drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but life-threatening hypersensitivity reaction, and its label requires a slow, low-dose start specifically to reduce this risk (the dataset captures eosinophilia, a component of DRESS, at 32 co-reports, PRR 4.6). The reaction is idiosyncratic, appears within the first weeks, and mandates immediate discontinuation.
Regulatory basis: cenobamate (Xcopri) prescribing information — DRESS/multiorgan hypersensitivity; required slow titration.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Onset within weeks of starting |
| Strength | met | PRR 4.6, modest |
| Consistency | met | Reproduced in case reports |
| Specificity | not established | Not specific to cenobamate |
| Biological gradient | partial | Risk rises with faster titration |
| Plausibility | not established | Idiosyncratic (not clearly dose-related) |
| Coherence | met | Idiosyncratic drug-hypersensitivity mechanism |
| Experiment | met | Part of the DRESS picture |
| Analogy | met | Analogous to other antiepileptic hypersensitivity |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✗ No ClinicalTrials.gov results-posting trial in the top search hits for cenobamate captured eosinophilia as a tracked adverse event in a usable structure. DRESS is too rare to appear in trial populations, so epilepsy trials did not capture it as a coded event.